The Prevalence and Distribution of Vitreoretinal Interface Abnormalities among Urban Community Population in China
Table 3
The prevalence of VIAs within males in this study (number of eyes or %).
Variables
Type 2 diabetes patients
Normal subjects
45–54 years
55–64 years
≥65 years
value
Total
45–54 years
55–64 years
≥65 years
value#
Total
value†
()
()
()
()
()
()
()
()
ERM
15 (20.3)
17 (16.3)
19 (22.09)
0.58
51 (19.31)
5 (5.10)
11 (11.70)
10 (12.5)
0.16
26 (9.56)
0.001
PTMH
0
1 (0.96)
2 (2.32)
3 (1.10)
1 (1.02)
0
1 (1.25)
2 (0.73)
0.62
FTMH
1 (1.35)
1 (0.96)
1 (1.16)
3 (1.10)
0
0
1 (1.25)
1 (0.38)
0.03
VMT
4 (5.41)
6 (5.77)
15 (17.44)
0.008
25 (9.47)
3 (3.06)
3 (3.19)
6 (7.5)
0.27
12 (4.41)
0.03
MC/ME
3 (4.05)
6 (5.77)
8 (9.30)
0.37
17 (6.44)
1 (1.02)
2 (2.12)
4 (5.00)
0.23
7 (2.57)
0.03
PVD
10 (13.51)
28 (26.92)
37 (43.02)
<0.01
75 (28.4)
13 (13.27)
37 (39.36)
40 (50.00)
<0.01
90 (33.09)
0.24
VIAs
33 (44.59)
59 (56.73)
82 (95.35)
<0.01
174 (65.9)
23 (23.47)
53 (56.38)
62 (77.5)
<0.01
138 (50.74)
<0.01
Epiretinal membrane without schisis (ERM); macular cysts/macular edema (MC/ME); partial thickness macular hole (PTMH); full-thickness macular hole (FTMH); posterior vitreous detachment (PVD); vitreomacular traction syndrome (VMT). Difference analysis between three age groups in Type 2 diabetes patients. #Difference analysis between three age groups in normal subjects. †Difference analysis between Type 2 diabetes patients and normal subjects groups.
